The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378) in the setting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068971/
https://ncbi.nlm.nih.gov/pubmed/24675041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0846
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados